Biography
Todd Thompson received a B.S. degree in Pharmacy (1987) from the University of New Mexico College of Pharmacy. He earned his PhD from the University of Wisconsin-Madison (1997) in Toxicology. Following his PhD degree he completed postdoctoral studies in Oncology at the University of Wisconsin Comprehensive Cancer Center.
Personal Statement
Research in my laboratory focuses on the development of both preventative and therapeutic measures for treating cancer, primarily for prostate cancer. Genetic considerations to guide cancer therapeutics are also investigated extending to the field of pharmacogenomics for cancer treatment based on both hereditary factors as well as genetics driving cancer progression that may serve in targeting cancer therapies.
Areas of Specialty
Oncology
Toxicology
Pharmacogenomics
Biochemistry
Pharmaceutics
Education
PhD, University of Wisconsin at Madison, 1997 (Toxicology)
BS, University of New Mexico, 1987 (Pharmacy)
Achievements & Awards
1.US Patent No. 9,440,942 (Issued Sept. 13, 2016) Todd A. Thompson and George Wilding. Chroman-derived anti-androgens for treatment of androgen-mediated disorders. (08-19-2014). Patent Application No. 14/327,942 (Filing date: 07-10-2014); Publication No. 2014/0323560 A1 (Publication date: 10/30/2014).
2.US Patent No. 9,326,974 (Issued May 3, 2016) Todd A. Thompson, Debra A. MacKenzie, Tudor I. Oprea, Larry A. Sklar, Bruce S. Edwards, Mark K. Haynes. Methods and related compositions for the treatment of cancer. Divisional of Application No. US 12/990,334 (Filing date: 06-05-2009); Patent No. 8835506. PCT Application No. PCT/US2009/003438 (Filing date: 06-05-2009) with publication no. WO 2009/148623 A2 (Publication date: 09-15-2011).
3.US Patent No. 8,835,506 (Issued Sept. 16, 2014) Todd A. Thompson, Debra A. MacKenzie, Tudor I. Oprea, Larry A. Sklar, Bruce S. Edwards, Mark K. Haynes. Methods and related compositions for the treatment of cancer. Application No. US 12/990,334; PCT Application No. PCT/US2009/003438 (Filing date: 06-05-2009) with publication no. WO 2009/148623 A2 (Publication date: 09-15-2011). US Patent Application No. 12/990,334 (Filing date: 06-05-2009).
4.US Patent No. 8,809,387 (Issued Aug. 19, 2014) Todd Thompson and George Wilding. Chroman-derived anti-androgens for treatment of androgen-mediated disorders. US Patent Application No. 13/966,775 (Aug. 19, 2014) (Filing date: 08-14-2013); Publication No. 2014/0045929 (Publication date: 02/13/2014).
5.US Patent No. 8,536,219 (Issued Sept. 17, 2013) Todd Thompson and George Wilding. Chroman-derived anti-androgens for treatment of androgen-mediated disorders. US Patent Application No. 13/542,432 (Filing date: 07-05-2012); Publication No. 20050192342 (Publication date: 11/01/2012).
6.US Patent No. 7,709,525 (Issued May 4, 2010) Todd Thompson and George Wilding. Chroman-derived anti-androgens for treatment of androgen-mediated disorders. US Patent Application No. 10/789,835 (Filing date: 02-27-2004); Publication No. 20050192342 (Publication date: 09-01-2005). PCT Application No. PCT/US2004/005872 with publication no. WO 2005/011658 (Filing date: 02-27-2004).
Courses Taught
Instructor of Record and developer of the Introduction to Pharmacogenomics (PHRM 536/736), which has provided advanced instruction to both graduate and pharmacy students in the field of pharmacogenomics since 2006.
Research and Scholarship
Fajardo, A.M., MacKenzie, D.A., Olguin, S., Scariano, J., Rabinowitz, I., Thompson, T.A. Antioxidants abrogate alpha-tocopherylquinone-mediated down-regulation of androgen receptor protein in androgen-responsive prostate cancer cells. PlosOne 2016 Mar 17; 11(3):e0151525. doi: 10.1371/journal.pone.0151525. eCollection 2016.
White, K.A., Luo, L., Thompson, T.A., Torres, S., Hu, C.A., Thomas, N.E., Lilyquist, J., Anton-Culver, H., Gruber, S.B., From, L., Busam, K.J., Orlow, I., Kanetsky, P.A., Marrett, L.D., Gallagher, R.P., Sacchetto, L., Rosso, S., Dwyer, T., Cust, A.E., Begg, C.B., Berwick, M., The GEM Study Group. Variants in Autophagy-Related Genes and Clinical Characteristics in Melanoma: A Population-Based Study. Cancer Medicine 5:3336-3345, 2016. doi: 10.1002/cam4.929, 2016.
Price, D.N., McBride, A.A., Anton, M., Kusewitt, D.F., Norenberg, J.P., MacKenzie, D.A., Thompson, T.A., Muttil, P. Longitudinal assessment of lung cancer progression in mice using the sodium iodide symporter reporter gene and SPECT/CT imaging. PlosOne 11(12):e0169107, 2016. doi: 10.1371/ journal.pone. 0169107, 2016.
Nighot, P.K., Borunda, T., Laidler, L., Wong, M., Thompson, T., Oprea, T., Sklar, L., Ma T.Y. Tocopherylquinone-mediated activation of aryl hydrocarbon receptor reduces intestinal epithelial tight junction permeability and severity of experimental colitis. Gastroenterology 154 (6):S-65, 2018.
Mandell MA, Saha B, Thompson TA. The tripartite nexus: autophagy, cancer, and tripartite motif-containing protein family members. Frontiers in Pharmacology 11:308, 2020. doi: 10.3389/fphar.2020.00308